Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Reliable cell and tissue morphology-based diagnosis of endemic Burkitt lymphoma in resource-constrained settings in Ghana

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The oncogene Gankyrin is expressed in testicular cancer and contributes to cisplatin sensitivity in embryonal carcinoma cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Increases in bioactive IGF do not parallel increases in total IGF-I during growth hormone treatment of children born SGA

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Semen quality in hypogonadal acromegalic patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Measurement of peripheral arterial tonometry in patients with diabetic foot ulcers during courses of hyperbaric oxygen treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A Polygenic Risk Score Suggests Shared Genetic Architecture of Voice Break With Early Markers of Pubertal Onset in Boys

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Rapid decline in 51Cr-ethylenediaminetetraacetic acid-measured renal function during the first weeks following liver transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Elevated serum levels of luteinizing hormone and slightly decreased serum levels of testosterone (mild Leydig cell insufficiency) is a common hormonal disturbance in testicular cancer (TC) survivors. A number of studies have shown that low serum levels of testosterone is associated with low grade inflammation and increased risk of metabolic syndrome. However, so far, no studies have evaluated whether testosterone substitution improves metabolic dysfunction in TC survivors with mild Leydig cell insufficiency.

METHODS/DESIGN: This is a single-center, randomized, double-blind, placebo-controlled study, designed to evaluate the effect of testosterone replacement therapy in TC survivors with mild Leydig cell insufficiency. Seventy subjects will be randomized to receive either testosterone replacement therapy or placebo. The subjects will be invited for an information meeting where informed consent will be obtained. Afterwards, a 52-weeks treatment period begins in which study participants will receive a daily dose of transdermal testosterone or placebo. Dose adjustment will be made three times during the initial 8 weeks of the study to a maximal daily dose of 40 mg of testosterone in the intervention arm. Evaluation of primary and secondary endpoints will be performed at baseline, 26 weeks post-randomization, at the end of treatment (52 weeks) and 3 months after completion of treatment (week 64).

DISCUSSION: This study is the first to investigate the effect of testosterone substitution in testicular cancer survivors with mild Leydig cell insufficiency. If positive, it may change the clinical handling of testicular cancer survivors with borderline low levels of testosterone.

TRIAL REGISTRATION: ClinicalTrials.gov : NCT02991209 (November 25, 2016).

Original languageEnglish
JournalB M C Cancer
Volume17
Issue number1
Pages (from-to)e461
ISSN1471-2407
DOIs
Publication statusPublished - 3 Jul 2017

    Research areas

  • Journal Article

ID: 50677327